Cash Cash Equivalents - GlaxoSmithKline PLC (NYSE:GSK) - Alpha Spread
G

GlaxoSmithKline PLC
NYSE:GSK

Watchlist Manager
GlaxoSmithKline PLC
NYSE:GSK
Watchlist
Price: 38.82 USD 1.17% Market Closed
Market Cap: 79.2B USD
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

GlaxoSmithKline PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GlaxoSmithKline PLC
Cash & Cash Equivalents Peer Comparison

Comparables:
A
AZN
INDV
HIK
AGY
DPH

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
GlaxoSmithKline PLC
NYSE:GSK
Cash & Cash Equivalents
ÂŁ3B
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
A
AstraZeneca PLC
NASDAQ:AZN
Cash & Cash Equivalents
$6.9B
CAGR 3-Years
-24%
CAGR 5-Years
5%
CAGR 10-Years
3%
Indivior PLC
LSE:INDV
Cash & Cash Equivalents
$302m
CAGR 3-Years
-33%
CAGR 5-Years
-21%
CAGR 10-Years
39%
Hikma Pharmaceuticals PLC
LSE:HIK
Cash & Cash Equivalents
$133m
CAGR 3-Years
-18%
CAGR 5-Years
-16%
CAGR 10-Years
-7%
Allergy Therapeutics PLC
LSE:AGY
Cash & Cash Equivalents
ÂŁ13.5m
CAGR 3-Years
-35%
CAGR 5-Years
-16%
CAGR 10-Years
10%
Dechra Pharmaceuticals PLC
LSE:DPH
Cash & Cash Equivalents
ÂŁ74.4m
CAGR 3-Years
-31%
CAGR 5-Years
-1%
CAGR 10-Years
9%

See Also

What is GlaxoSmithKline PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
3B GBP

Based on the financial report for Jun 30, 2024, GlaxoSmithKline PLC's Cash & Cash Equivalents amounts to 3B GBP.

What is GlaxoSmithKline PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-1%

Over the last year, the Cash & Cash Equivalents growth was -6%. The average annual Cash & Cash Equivalents growth rates for GlaxoSmithKline PLC have been -5% over the past three years , -6% over the past five years , and -1% over the past ten years .

Back to Top